1. Identification of Potential Key Biomarkers and Immune Infiltration in Oral Lichen Planus
   Lou Geng et al, 2022, Disease Markers CrossRef
2. PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer
   Xianping Xu et al, 2024, Cancer Chemotherapy and Pharmacology CrossRef
3. Study on the activation of cell death mechanisms: in search of new therapeutic targets in glioblastoma multiforme
   Ludovica Gaiaschi et al, 2023, Apoptosis CrossRef
4. Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization
   Yi Zhang et al, 2023, Frontiers in Oncology CrossRef
5. Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?
   Juliana B. Vilar et al, 2022, Cancers CrossRef
6. Cytoplasmic Shotgun Proteomic Points to Key Proteins and Pathways in Temozolomide-Resistant Glioblastoma Multiforme
   Milan Teraiya et al, 2024, Journal of Proteome Research CrossRef
7. Anti-Proliferative Effects of E2F1 Suppression in Glioblastoma Cells
   Paulo R.D.V. Godoy et al, 2021, Cytogenetic and Genome Research CrossRef
8. Advances in synthetic lethality modalities for glioblastoma multiforme
   Seidu A. Richard, 2024, Open Medicine CrossRef
9. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review
   Jiaqi Xiong et al, 2022, Seminars in Cancer Biology CrossRef